Bacillus of Calmette-Guérin immunotherapy: which protocol?;Immunothérapie par Bacille de Calmette-Guérin : quel protocole ?

Progres en Urologie

Volumn 18, Issue SUPPL. 5, 2008, Pages

  Saint, Fabien ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

BCG; Immunotherapy; Maintenance; Mitomycin C; NMIBC; Nonmuscle invasive bladder cancer; Superficial bladder cancer

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BCG VACCINE; IMMUNOLOGICAL ADJUVANT; MITOMYCIN;

ARTICLE; BLADDER TUMOR; CANCER INVASION; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; META ANALYSIS; MORTALITY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; TIME; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; CLINICAL PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; META-ANALYSIS AS TOPIC; MITOMYCIN; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 45949093520     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1166-7087(08)72485-0     Document Type: Article

References (26)

1. Zbar B. Tumor regression mediated by Mycobacterium bovis (strain BCG). Natl Cancer Inst Monogr 35 (1972) 341-344
2. Bloomberg S.D., Brosman S.A., Hausman M.S., Cohen A., and Battenberg J.D. The effects of BCG on the dog bladder. Invest Urol 12 (1975) 423-427
3. Patard J.J., Muscatelli-Groux B., Saint F., Popov Z., Maille P., Abbou C., et al. Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer. Br J Urol 78 (1996) 709-714
4. de Reijke T.M., de Boer E.C., Kurth K.H., and Schamhart D.H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155 (1996) 477-482
5. Haanen J.B., de Waal Malefijt R., Res P.C., Kraakman E.M., Ottenhoff T.H., de Vries R.R., et al. Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med 174 (1991) 583-592
6. Hawkyard S.J., Jackson A.M., Hawkins R.A., James K., Smyth J.F., and Chisholm G.D. Expression of interferon-gamma receptors on bladder cancer cells: does it correlate with biological response?. Urol Res 20 (1992) 229-232
7. Stavropoulos N.E., Ioachim E., Pavlidis N., Pappa L., Kalomiris P., and Agnantis N.J. Local immune response after intravesical interferon gamma in superficial bladder cancer. Br J Urol 81 (1998) 875-879
8. Patard J.J., Saint F., Velotti F., Abbou C.C., and Chopin D.K. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 26 (1998) 155-159
9. Saint F., Patard J.J., Maille P., Soyeux P., Hoznek A., Salomon L., et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 167 (2002) 364-367
10. Saint F., Kurth N., Maille P., Vordos D., Hoznek A., Soyeux P., et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 10 107 (2003) 434-440
11. Thurnher M., Ramoner R., Gastl G., Radmayr C., Böck G., Herold M., et al. Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. Int J Cancer 70 (1997) 128-134
12. Patard J.J., Muscatelli-Groux B., Saint F., Popov Z., Maille P., Abbou C., et al. Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer. Br J Urol 78 (1996) 709-714
13. Kramnik I., Radzioch D., and Skamene E. T-helper 1-like subset selection in Mycobacterium bovis bacillus Calmette-Guérin-infected resistant and susceptible mice. Immunology 81 (1994) 618-625
14. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
15. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
16. Böhle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-686
17. Badalament R.A., Herr H.W., Wong G.Y., Gnecco C., Pinsky C.M., Whitmore Jr. W.F., et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 5 (1987) 441-449
18. Akaza H., Hinotsu S., Aso Y., Kakizoe T., and Koiso K. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 15 75 (1995) 552-559
19. Palou J., Laguna P., Millán-Rodríguez F., Hall R.R., Salvador-Bayarri J., and Vicente-Rodríguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 165 (2001) 1488-1491
20. Losa A., Hurle R., and Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder:long-term results. J Urol 163 (2000) 68-71
21. Ojea A., Nogueira J.L., Solsona E., Flores N., Gómez J.M., Molina J.R., et al., CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
22. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder:a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
23. Saint F., Irani J., Patard J.J., Salomon L., Hoznek A., Zammattio S., et al. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 57 (2001) 883-888
24. Morales A., Nickel J.C., and Wilson J.W. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 147 (1992) 1256-1258
25. Pagano F., Bassi P., Piazza N., Abatangelo G., Drago Ferrante G.L., and Milani C. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 27 Suppl 1 (1995) 19-22
26. Martínez-Piñeiro J.A., Flores N., Isorna S., Solsona E., Sebastián J.L., Pertusa C., et al., For CUETO (Club Urológico Español de Tratamiento Oncológico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680